Do we fully understand the economic value of vaccines?

Vaccine

Volumn 25, Issue 32, 2007, Pages 5945-5957

  Drummond, Michael ^a,c   Chevat, Catherine ^b   Lothgren, Mickael ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b SANOFI PASTEUR   (France)

^c i3 Innovus   (United Kingdom)

Author keywords

Cost effectiveness; Reimbursement

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

CHEMOPROPHYLAXIS; CHILDHOOD; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEVELOPED COUNTRY; DRUG COST; ECONOMIC EVALUATION; GROUPS BY AGE; HEALTH CARE POLICY; HEALTH ECONOMICS; HEPATITIS A; HEPATITIS B; HERD IMMUNITY; HUMAN; IMMUNIZATION; INFLUENZA; MENINGOCOCCOSIS; METHODOLOGY; MODEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; STREPTOCOCCUS INFECTION; VACCINATION;

COST-BENEFIT ANALYSIS; HUMANS; VACCINATION; VACCINES;

EID: 34447536545     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.070     Document Type: Review

References (26)

1. Rawlins M.D., and Culyer A.J. National Institute for Clinical Excellence and its value judgments. BMJ 329 (2004) 224-227
2. Beutels P., Van Doorslaer E., Van Damme P., and Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2 (2003) 649-660
3. Brisson M., and Edmunds W.J. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 23 (2003) 76-82
4. Ehreth J. The global value of vaccination. Vaccine 21 (2003) 596-600
5. Ehreth J. The value of vaccination: a global perspective. Vaccine 21 (2003) 4105-4117
6. Batson A. Win-win interactions between the public and private sectors. Nat Med 4 (1998) 487-491
7. Scheifele D.W. New vaccines and the rising cost of caring. Paediatr Child Health 5 (2000) 371-372
8. Coffield A.B., Maciosek M.V., McGinnis J.M., Harris J.R., Caldwell M.B., Teutsch S.M., et al. Priorities among recommended clinical preventive services. Am J Prev Med 21 (2001) 1-9
9. Chabot I., Goetghebeur M.M., and Gregoire J.P. The societal value of universal childhood vaccination. Vaccine 22 (2004) 1992-2005
10. McIntosh E.D. Cost-effectiveness studies of pneumococcal conjugate vaccines. Expert Rev Vaccines 3 (2004) 433-442
11. Jacobs R.J., and Meyerhoff A.S. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. Prev Med 33 (2001) 639-645
12. Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 22 (2004) 3312-3322
13. Miller MA, Hinman AR. Economic analyses of vaccine policies. Vaccines. Saunders/Elsevier; 2004.
14. De Graeve D., and Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 22 (2004) 719-740
15. Postma M.J., Heijnen M.L., Beutels P., and Jager J.C. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands. Expert Rev Vaccines 2 (2003) 477-482
16. Getsios D., Caro I., El Hadi W., and Caro J.J. Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research. Int J Technol Assess Health Care 20 (2004) 280-288
17. Welte R., Trotter C.L., Edmunds W.J., Postma M.J., and Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics 23 (2005) 855-874
18. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 37 (2003) 44-51
19. Deneke M.G., and Arguedas M.R. Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs. Expert Rev Vaccines 2 (2003) 661-672
20. Postma M.J., Jansema P., van Genugten M.L., Heijnen M.L., Jager J.C., and de Jong-van den Berg L.T. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 62 (2002) 1013-1024
21. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 (2003) 1769-1775
22. Stone P.W., Teutsch S., Chapman R.H., Bell C., Goldie S.J., and Neumann P.J. Cost-utility analyses of clinical preventive services: published ratios, 1996-1997. Am. J Prev. Med. 19 (2000) 15-23
23. Graham J.D., Corso P.S., Morris J.M., Segui-Gomez M., and Weinstein M.C. Evaluating the cost-effectiveness of clinical and public health measures. Annu. Rev. Public Health 19 (1998) 125-152
24. Melegaro A., and Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccine in England and Wales. Vaccine 22 (2004) 4203-4214
25. Cohen D.R., and Henderson J.B. Health Prevention and Economics (1988), Oxford University Press, Oxford
26. Bos J.M., Beutels P., Annemans L., and Postma M.J. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. PharmacoEconomics 22 (2004) 1171-1179